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ABSTRACT 
Bepotastine Besilate is an anti-histaminic drug and it is marketed as tablet of strength 10mg. In this study an attempt is made to monitor the 
dissolution of Bepotastine Besilate tablet. Dissolution study was done for marketed sample using phosphate buffer 6.8, phosphate buffer 4.5 
and 0.1 N HCl as dissolution media. Samples were analysed using UV spectrophotometer, HPLC and HPTLC. Detection wavelength selected was 
226nm. A chromatographic separation is achieved on a C18 column with a mobile phase consisting of acetonitrile, w ater with isocratic elution 
with flow rate 1ml/min. Solvents used for development in HPTLC were chloroform and methanol. Percentage release of bepotastine besilate 
was calculated by extrapolation of calibration curve. The results of three analytical methods were compared by applying One-Way ANOVA. 
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INTRODUCTION 
Bepotastine is a second-generation nonsedating 
antihistamine. It possesses a dual mode of action as it also 
stabilizes mast cell function and suppresses migration of 
eosinophils into the inflamed tissues[1]. Its molecular formula 
is C21H25ClN2O3. Chemically it is benzenesulfonic acid;4-[4-
[(S)-(4-chlorophenyl)- pyridin-2-ylmethoxy]piperidin-1-
yl]butanoic acid as shown in fig.1. 
 
Fig 1: Structure of  Bepotastine Besilate 
Molecular weight is 547.063 g/mol[2]. It is soluble in 
Acetonitrile and methanol. It was approved in Japan for use 
in the treatment of allergic rhinitis and urticaria/pruritus. It 
is available as ophthalmic solution and oral tablet. It is a 
direct H1 receptor antagonist that inhibits the release of 
histamine from mast cells. Literature survey revealed the 
estimation of Bepotastine by several techniques such as 
simultaneous estimation RP-HPLC techniques[3,4], Stability 
indicating method by HPTLC[5], development of alternative 
salt i.e. Bepotastine salicylate[6], comparison of branded and 
generic[7].  
MATERIAL AND METHOD 
All AR grade chemicals and reagents i.e. Methanol, 
Chloroform, Acetone, Hydrochloric acid(HCL), Sodium 
hydroxide (NaOH), Potassium Dihydrogen Phosphate 
(KH2PO4) were purchased from LOBA CHEMIE PVT. LTD., 
Mumbai. 
Selection of Wavelength 
Standard stock solution of 1,000ug/ml was prepared by 
using ACN. Further dilution was carried out to make solution 
of 10μg/ml and was scanned over 200 to 400nm in UV-
Spectrophotometer. Wavelength 226nm showed 
considerable absorbance hence it was selected as analytical 
wavelength. UV spectrum is given as 
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Fig 2: Spectrum of Bepotstine Besilate (10μg/ml in ACN) 
Preparation of Stock Solution: 
UV and HPLC- 10 mg of Bepotastine besilate was dissolved in 
10 ml ACN to make 1000 μg/ml. Further dilutions were 
made in ACN to make 100 μg/ml. Further dilutions 3, 6, 9, 12, 
15 μg/ml were made to take absorbance and peak area in 
UV-Visible spectrophotometer and HPLC respectively.  
HPTLC- 10 mg of Bepotastine besilate was dissolved in 10 ml 
ACN to make 1000 μg/ml. Further dilutions were made in 
ACN to make 50 μg/ml. Solution from 50μg/ml applied on 
TLC plate to get 200 to 800ng/band. 
Chromatographic Condition  
HPLC 
HPLC system used was Jasco consisting PU 2082 Plus pump, 
Rheodyne (Capacity – 50ul) injector, Jasco UV 2075 plus 
detector and software Borwin (Version – 1.5). The 
chromatographic separation was optimized using Nucleosil 
C18 column (250x4.6mm) and mobile phase was composed 
of Acetonitrile: Water (0.1ml OPA v/v is added in 100 ml 
water then pH is adjusted to 3 by Triethylamine) in 
proportion of 80:20v/v. The flow rate of the mobile phase 
and the column temperature was set as 1.0 ml/min and 45°C. 
The detection wavelength was done at 226 nm. 
 
Fig 3: Chromatogram of standard linearity of Bepotastine 
Besilate (3, 6, 9, 12μg/ml in ACN) 
HPTLC 
Optimisation of chromatographic condition was carried out 
on aluminum plates precoated with silica gel 60F254 in (20 
cm × 10 cm with 250μm layer thickness). Sample was 
applied on the plate as a band of 6 mm width using Camag 
100 μl sample syringe (Hamilton, Switzerland) with Linomat 
5 applicator (Camag Switzerland). The mobile phase was 
composed of Chloroform: methanol 5:5v/v. Mobile phase 
was saturated in Camag            (20cm × 10cm) twin trough 
glass chamber for 15 min. saturation condition and run to 
distance was 90 mm. Densitometric scanning was performed 
using Camag TLC scanner 3 in the range of 400-200 nm, 
operated by winCATS (version 1.4.3.6336). 
 
 
Fig 4: 3D Densitogram of Bepotastine Besilate (track 1 is blank ACN, track 2-6 linearity 200-800 ng/band) 
 
Dissolution Studies 
Preparation of Dissolution Media[8-11]: 
 Buffer 6.8-  50ml of 0.2M KH2PO4 is mixed with 22.4 ml 
of 0.2M NaOH and volume was made upto 200ml 
 Buffer 4.5- 6.8gm of  KH2PO4 in 1000 ml water. 
 0.1 N HCl – 8.5ml of concentrated HCl in 1000ml water. 
Procedure of Dissolution: 
The dissolution test was performed on Dissolution Testing 
Apparatus 2 (paddle method) using 900 ml medium at 37 
±0.5°C and 50 rpm.  Six marketed tablets of Bepotastine 
Besilate of strength 10 mg were added to six vessels. 10ml 
sample was withdrawn after 30 mins. Sample was filtered 
through whatman filter paper and monitored using UV-
Visible spectrophotometer, HPLC, HPTLC. The procedure is 
repeated six times for each dissolution media. 
RESULT AND DISCUSSION 
1) Phosphate buffer 6.8 
a) UV method  
y = 0.012x - 0.012 
R² = 0.997  
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Table 1: Percent release of BB in Phosphate buffer 6.8 by UV 
method 
No. of flasks % release 
1 99.65 
2 96.25 
3 101.17 
4 99.88 
5 98.79 
6 100.51 
 
b) HPLC method 
y = 58035x + 35550 
 
R² = 0.997 
Table 2: Percent release of BB in Phosphate buffer 6.8 by 
HPLC method 
No. of flasks % release 
1 97.30 
2 96.27 
3 95.62 
4 94.94 
5 95.74 
6 95.63 
 
 
Fig 5: Chromatogram of Bepotastine Besilate in Phosphate 
buffer 6.8 (15μg/ml) 
C) HPTLC method 
y = 1.765x + 120.0                 R² = 0.998 
Table 3: Percent release of BB in Phosphate buffer 6.8 by 
HPTLC method 
No. of flasks % release 
1 89.17 
2 88.98 
3 89.14 
4 89.69 
5 89.69 
6 88.78 
 
 
Fig 6: 3D Densitogram of standard linearity and dissolution samples of Bepotastine Besilate in Phosphate buffer 6.8(track 1 is 
blank ACN, track 2-6 linearity 200-800 ng/band, track 7-12 dissolution samples) 
 
2) Phosphate buffer 4.5 
a) UV method  
y = 0.009x + 0.008 
R² = 0.999 
Table 4: Percent release of BB in Phosphate buffer 4.5 by 
UV method 
No. of flasks % release 
1 100.00 
2 100.34 
3 98.42 
4 100.68 
5 98.91 
6 97.69 
 
b) HPLC method  
y = 45009x + 87790 
R² = 0.996 
Table 5: Percent release of BB in Phosphate buffer 4.5 by 
HPLC method 
No. of flasks % release 
1 95.08 
2 95.93 
3 92.46 
4 95.42 
5 94.64 
6 93.95 
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Fig 7: Chromatogram of Bepotastine Besilate in Phosphate buffer 4.5 (15μg/ml) 
 
c) HPTLC method 
 y = 1.640x + 351.8 
 R² = 0.995  
Table 6: Percent release of BB in Phosphate buffer 4.5 by HPTLC method 
No. of flasks % release 
1 89.12 
2 88.89 
3 88.12 
4 89.54 
5 89.01 
6 89.56 
 
 
Fig 8: 3D Densitogram of standard linearity and dissolution samples of Bepotastine Besilate in Phosphate buffer 4.5 (track 1,2 is 
blank ACN, track 3-7 linearity 200-800 ng/band, track 8-13 dissolution samples) 
3) 0.1 N HCl 
a) UV method 
 y = 0.027x - 0.032 
 R² = 0.996  
Table7: Percent release of BB in 0.1 N HCl by UV method 
No. of flasks % release 
1 97.91 
2 99.33 
3 97.76 
4 99.01 
5 97.20 
6 101.81 
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b) HPLC method  
 
Fig 9: Chromatogram of Bepotastine Besilate in Phosphate buffer 0.1 N HCl(15μg/ml) 
 HPLC study of Bepotastine Besilate By using 0.1N HCl as dissolution medium showed that the degradation product of 
Bepotastine Besilate eluted at 4.46mins where as standard BB was expected to be eluted at 7 mins. 
c) HPTLC method:  
 
Fig 10: 3D Densitogram of linearity and dissolution samples of Bepotastine Besilate in 0.1 N HCl (track 1,2 is blank ACN, track 3-
7 linearity 200-800 ng/band, track 8-10 dissolution samples) 
HPLC study of Bepotastine Besilate By using 0.1N HCl as dissolution medium did not show any peak at Rf of bepotastine 
besilate. 
Table 9: Percentage release of bepotastine besilate tablet 
Media Buffer 6.8 Buffer 4.5 0.1 N HCl 
No. of 
flasks 
UV HPLC HPTLC UV HPLC HPTLC UV HPLC HPTLC 
1 99.65 97.30 89.17 100.01 95.08 89.12 97.91 - - 
2 96.25 96.27 88.97 100.34 95.93 88.89 99.32 - - 
3 101.17 95.62 89.14 98.42 92.46 88.12 97.76 - - 
4 99.88 94.94 89.69 100.68 95.42 89.54 99.01 - - 
5 98.79 95.74 89.69 98.91 94.64 89.01 97.20 - - 
6 100.51 95.64 88.78 97.69 93.95 89.56 101.81 - - 
Mean 99.37 95.92 89.24 99.34 94.58 89.04 98.84 - - 
SD 1.73 0.80 0.37 1.18 1.24 0.53 1.60 - - 
 
Statistical Analysis 
Statistical analysis was carried out using GraphPad Instat 3. 
All of the data is shown as the mean ± standard Deviation 
and were analysed using one-way analysis of variance 
(ANOVA). Significant differences between three analytical 
methods were determined using Tukey-Kramer multiple 
comparisons test, P<0.05 was considered significant.
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Fig 11: Graphical comparison of % release in phosphate 
buffer 6.8 by three analytical methods  
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Fig 12: Graphical comparison of % release in phosphate 
buffer 4.5 by three analytical methods
  
Table 10: Comparison of % release by analytical methods to monitor dissolution in different dissolution media 
Sr. No. Dissolution 
media 
UV method HPLC method HPTLC method 
1 Phosphate buffer 
6.8 
99.37 ± 1.73 95.92 ± 0.79 89.24 ± 0.37 
2 Phosphate buffer 
4.5 
99.34 ± 1.18 94.57 ± 1.23 89.04 ± 0.52 
 
Observation 
With phosphate buffer 6.8 and 4.5, the peak shape of 
Bepotastine Besilate was not symmetric in HPLC. Peak purity 
in HPTLC is retained. 
CONCLUSION 
 Dissolution study of Bepotastine Besilate was monitored 
and compared by three analytical methods UV spectroscopy, 
HPLC, HPTLC for three different dissolution media. From the 
observations we concluded that all three analytical methods 
for Phosphate buffer 6.8 and 4.5 when compared with each 
other, found to have significantly different from each other. 
In case of 0.1 N HCl as dissolution media, HPLC and HPTLC 
showed degradation of Bepotastine Besilate in the 
dissolution media. Thus 0.1 N HCl is not suitable dissolution 
media for Bepotastine Besilate. UV spectrophotometry, being 
non-specific technique, was not able to detect change in 0.1 N 
HCl. Thus chromatographic technique is recommended for 
analysing dissolution samples. 
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